埃诺泽提尼布是一种选择性,穿透大脑的EGFR抑制剂,用于治疗EGFR Exon 20和非典型突变的非小细胞肺癌
Melissa R Junttila1, Claire E Repellin1, Sumeet Salaniwal1
1ORIC Pharmaceuticals, Inc., South San Francisco, CA, United States.
Cancer research
|November 6, 2025
概括
埃诺韦丁尼布有效地向非小细胞肺癌 (NSCLC) 的EGFR外基子20插入,显示出显著的瘤回归和大脑转移的完整反应. 这种药物为患有这些难以治疗的突变的NSCLC患者提供了有前途的新疗法.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 表皮生长因子受体 (EGFR) 突变驱动非小细胞肺癌 (NSCLC).
- 大脑转移在NSCLC患者中很常见,特别是那些具有非经典EGFR突变的患者,例如外20插入.
- 由于预后较差,非经典EGFR突变存在重大未满足的医疗需求.
研究的目的:
- 描述埃诺泽提尼布 (ORIC-114),一种新型EGFR抑制剂的发现和开发.
- 评估埃诺泽提尼布对EGFR外20插入和其他非典型突变的疗效.
- 评估埃诺泽提尼布的脑透率和在脑转移的NSCLC中治疗潜力.
主要方法:
- 埃诺泽提尼布的发现和临床前开发,这是一个口服生物可用,不可逆转的EGFR抑制剂.
- 在体外和体内研究评估埃诺泽提尼布在非典型EGFR突变模型中的功效和瘤回归.
- 一期临床试验,评估埃诺泽提尼布在具有非典型EGFR突变的晚期NSCLC患者中.
主要成果:
- 在各种不典型的EGFR突变模型中,埃诺韦丁尼布表现出强烈的效力和显著的瘤回归.
- 该药物表现出高基因组选择性,特别针对EGFR外20突变.
- 在一项I期试验中,一个EGFR外基因组20插入的患者在系统性和大脑转移方面实现了持续的完整反应.
结论:
- 埃诺韦丁尼布是一种强大的脑透抑制剂,向EGFR外基因组20插入和其他非典型突变.
- 该药物在治疗脑转移和EGFR外基子20插入的NSCLC患者方面显示出显著的前景.
- 埃诺韦丁尼布代表了NSCLC中高未满足需求人群的潜在新疗法选择.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
9.2K
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10.6K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
428
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
428
